
Six-to-eight new immunizations may complete clinical studies and undergo regulatory review by the end of the year, Soumya Swaminathan, the Geneva-based agency’s chief scientist, said.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3qPwGNd
via
IFTTT
0 comments:
Post a Comment